News

Hypertension — high blood pressure — triples the risk of severe walking disability in Hispanic and Latino people with multiple sclerosis (MS), a new observational study reports. The study, “Hypertension and hypertension severity in Hispanics/Latinx with MS,” was published in the Multiple Sclerosis Journal. Although…

Skin reactions are common among relapsing-remitting multiple sclerosis (RRMS) patients being treated with oral Mavenclad (cladribine), affecting about one-third of the people evaluated in a real-world study in Germany. These findings suggest the need for careful clinical surveillance to rapidly diagnose and possibly treat skin problems stemming from Mavenclad’s use,…

Multivitamin supplements reduce fatigue and improve quality of life in people with relapsing-remitting multiple sclerosis (RRMS), a new study reports. After 70 days of continuous use, patients taking multivitamin supplements containing vitamins A, B-complex, C, and D improved their blood antioxidant status and experienced up to a 34% reduction…

Genetic susceptibility to multiple sclerosis (MS) depends on an individual’s particular combination of multiple risk variants, a study reveals. The study, “Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions,” was published in the journal BMC Medical…

Low doses selected and underlying inflammatory disease may have confounded the ability of temelimab to significantly affect neuroinflammation in a Phase 2 trial in relapsing-remitting multiple sclerosis (RRMS) patients. GeNeuro‘s investigational MS therapy did, however, show other evidence of clinical benefit that supports its continued development, researchers…

Fatigue, whether alone or in combination with depression or anxiety, is the main influencing factor of self-reported working ability among people with relapsing-remitting multiple sclerosis (RRMS) and mild disability, according to a study in the Netherlands. Notably, contrary to the researchers’ expectations, personality traits were found to have…

The first World Brain Day, created by the World Federation of Neurology (WFN), occurred seven years ago, and since then has been devoted to raising awareness about disorders such as Parkinson’s disease, stroke, and epilepsy. This year, WFN, which represents 122 national neurological societies, is turning its…

The strength of the muscles used to exhale a breath may predict physical ability and disease severity in people with multiple sclerosis (MS), a study reported. Patients in this study with weaker expiratory muscles were also those with greater physical disability and more severe disease. The study, “Pulmonary…

Nerve tissue scars associated with multiple sclerosis (MS) show marked differences from those of similar neurodegenerative disorders, according to a recent study. MS-associated inflammation causes brain and spinal cord lesions (nerve tissue scarring) that often are bigger and last longer than those of two other demyelinating diseases: myelin oligodendrocyte…

NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who will work with the company as it prepares to start a Phase 2 clinical trial next year testing its lead compound, NVG-291, in people with MS. “We are honored to…

OM1, a technology company focused on chronic conditions, announced that it has launched a multiple sclerosis (MS) registry to generate data that may ultimately be used to improve care and develop treatments for the disease. The OM1 registry is being touted as the largest, most representative MS data…

Isoflavone-rich diets boost gut health and lessen multiple sclerosis (MS) severity, a new study in mice suggests. In the study, mice with MS that were fed a diet rich in isoflavone — a plant-based compound — developed diverse and abundant gut bacteria, particularly isoflavone-digesting bacteria, which produced compounds that…

Treatment with anti-CD20 antibodies reduced the loss of myelin and improved the survival of neurons in a rat model of multiple sclerosis (MS), a new study reports. The findings imply that B-cells — the immune cells that are killed by anti-CD20 antibodies — play a central role in the…

Actively taking steps to cope with the chronic stress of multiple sclerosis (MS) — from keeping a sense of humor to seeking emotional and tangible support — can help to improve patients’ quality of life, a small questionnaire-based study from Poland suggests. The study, “The Role of…

Adults in Scotland with active relapsing-remitting multiple sclerosis (RRMS) will now have access at low or no cost to Kesimpta (ofatumumab), the first self-administered, at-home B-cell-targeting therapy for people with the neurodegenerative disease. The Scottish Medicines Consortium (SMC) recommended that the Novartis therapy be available through the…

Biogen has signed a deal with InnoCare Pharma to acquire global commercialization and licensing rights to orelabrutinib, an experimental oral BTK inhibitor (BTKi) now being tested in people with relapsing-remitting multiple sclerosis (RRMS) in a Phase 2 clinical trial. Under the terms of the agreement, Biogen will have…

Tecfidera has a lower risk of discontinuation due to treatment failure than Aubagio in people with multiple sclerosis (MS), a new observational study in Norway suggests. In the study, people receiving Tecfidera (dimethyl fumarate) were 38% less likely to experience treatment failure and stop use than those receiving…

Selma Blair, the TV and film actor who is also a multiple sclerosis (MS) advocate, will headline next month’s second International Virtual Summit for young adults with chronic and rare disorders. Hosted by Health Advocacy Summit (HAS), the Aug. 7-8 event will focus on empowerment, resources, and connection. The event is…

A component of yeast cell walls — called MGCP — prevented disease in a mouse model of multiple sclerosis (MS) by activating anti-inflammatory immune T-cells while suppressing inflammatory T-cells, a study showed. This work also supporting the microbiome’s role in affecting inflammation in autoimmune diseases like MS. “We have…

A potential anti-inflammatory treatment, xB3-IL-1RA was able to reach the central nervous system of a rodent model of multiple sclerosis (MS), and with repeat doses delay disease onset and ease clinical symptoms, according to the investigational therapy’s developer Bioasis Technologies. These findings support the utility of Bioasis’ xB3 peptide…

Three scientists in the U.K. were given awards by the International Progressive MS Alliance that will support projects aiming to explore new approaches to treating progressive forms of multiple sclerosis (MS). The three are among this year’s 19 winners of the alliance’s Research Challenge Awards, which totaled £1.2 million…

Nvidia announced the launch of the U.K.’s most powerful supercomputer — called Cambridge-1 — which uses a combination of artificial intelligence (AI) and simulation to help scientists to better understand complex diseases such as multiple sclerosis (MS) and to design new therapeutics. Cambridge-1 is the first supercomputer designed…

MediciNova announced that it will be given a U.S. patent covering the use of ibudilast (MN-166) in treating eye disease. This oral medication aims to lessen inflammation, including that of progressive multiple sclerosis (MS). Specifically, it will cover ibudilast’s use in  treating injury or damage to the macula —…

Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or…

High-potency therapies are more effective at reducing the frequency of symptom relapses in people with secondary progressive multiple sclerosis (SPMS) than low-potency medications, a 10-year study showed. Notably, there was no difference in the effectiveness of either high- or low-potency medicines to limit the progression of disability. “When the…

Using high-efficacy therapies as a first treatment for multiple sclerosis (MS) patients significantly increases the likelihood of having no evidence of disease activity after one and two years, compared to using moderately effective therapies, according to a real-world study of Norwegian patients. However, with each additional attempted treatment, the…

Blacks with multiple sclerosis (MS) have more severe disease and greater disability at their first visit than white patients, even when differences in socioeconomic status are taken into account, a large U.S. study found. The data showed that Black patients with MS had lower scores on some measures of…

Researchers have identified a molecular switch that awakens stem cells in a specific region of the mouse brain — and with their activation, two new types of glia, non-neuronal cells that play critical roles in brain function, also were discovered. Notably, the development of these new glial cell types also…

Alan Thompson, dean of the Faculty of Brain Sciences at University College London (UCL), has won the 2021 Charcot Award, a prize given once every two years for a lifetime of achievement in research into the understanding and treatment of multiple sclerosis (MS). “The Charcot Award is viewed by…

The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medication IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS), as well as a separate trial for people with progressive types of MS. The RRMS clinical trial program, expected…